Summary
Cimetropium bromide is an antimuscarinic compound with antispasmodic properties. Its effect on meal-stimulated sigmoid motor activity in 30 patients with the irritable bowel syndrome, mainly with pain and constipation, has been evaluated.
The mechanical activity of the sigmoid colon was recorded with a probe with three open-tipped tubes ending 45, 30, and 15 cm from the anal margin.
After a recording period of 60 min, 5 mg cimetropium bromide or saline was given i.v., according to a randomized, double-blind design 5 min before a 1000 calorie meal, and motility was then recorded for 2 h.
The meal caused a significant increase in motor activity for 90 min in the saline-treated group. Cimetropium bromide abolished the peak of motor activity 10–20 min after the meal and significantly inhibited postprandial colonic motility for at least 2 h (p<0.01).
This effect provides a rationale for the use of cimetropium bromide in treatment of the irritable bowel syndrome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Connel AM, Jones F, Rowlands EN (1965) Motility of the pelvic colon, part IV. Abdominal pain associated with colonic hypermotility after meal. Gut 6: 105–112
Holdstock DJ, Misiewicz JJ, Waller SL (1969) Observations on the mechanism of abdominal pain. Gut 10: 19–31
Wangel AG, Deller DJ (1965) Intestinal motility in man. III. Mechanisms of constipation and diarrhea with particular reference to the irritable colon syndrome. Gastroenterology 48: 69–84
Harvey RF, Read AE (1973) Effect of cholecystokinin on colonic motility and symptoms in patients with irritable bowel syndrome. Lancet 1: 1–3
Harvey RF, Read AE (1973) Effect of oral magnesium sulphate on colonic motility in patients with the irritable bowel syndrome. Gut 14: 983–987
Snape WJ, Matarazzo SA, Cohen S (1978) Effect of eating and gastrointestinal hormones on human colonic myoelectrical and motor activity. Gastroenterology 75: 373–378
Wright SH, Snape WJ, Battle W, Cohen S, London RL (1980) Effect of dietary components on gastrocolonic response. Gastrointest Liver Physiol 1: G228-G232
Sullivan MA, Cohen S, Snape MJ (1978) Colonic myoelectrical activity in irritable bowel syndrome. Effect of eating and anticholinergics. N Engl J Med 298: 878–883
Narducci F, Bassotti G, Pelli MA, Morelli A (1986) Colonic motility and gastric emptying in the irritable bowel syndrome. Dig Dis Sci 31: 241–246
Swarbrick ET, Bat L, Hegarty JE, Williams CB, Dawson AM (1980) Site of pain from the irritable bowel. Lancet 1: 443–446
Schiavone A, Schiavi GB, De Conti L, Micheletti R, Sagrada A, Hammer R, Giachetti A (1985) Cimetropium: Characterization of antimuscarinic and spasmolytic properties. Arzneimittelforsch/Drug Res 35 [I]: 796–799
Scarpignato C, Bianchi Porro G (1985) Cimetropium bromide, a new antispasmodic compound: Pharmacology and therapeutic perspectives. Int J Clin Pharm Res 5: 467–477
Piai G, Visconti M, Minieri M, Sollazzo R, Mazzacca G, Imbimbo BP (1986) Treatment of irritable bowel syndrome. A double-blind cross-over trial of cimetropium bromide (Alginor) v. prifinium bromide. Clin Trials J 23: 6–10
Ferrari A, Cavallero M, Spandre M, Gemme C, Rossini FP, Imbimbo BP (1986) Double-blind study of a new antimuscarinic, cimetropium bromide, in patients with irritable bowel syndrome. Clin Ther 8: 320–328
Valentini M, Piazzi L, Imbimbo BP, Dobrilla G (1986) Efficacy of cimetropii bromidum for long term treatment of irritable bowel syndrome (IBS). Gastro-entero-hepatol 4 [Suppl]: 37
Lanfranchi GA, Bazzocchi G, Brignola C, Campieri M, Labo G (1984) Different patterns of intestinal transit time and anorectal motility in painful and painless chronic constipation. Gut 25: 1352–1357
Bazzocchi G, Fois F, Campieri M, Brignola C, Lanfranchi GA (1986) Recording of sigmoid motility in basal condition and after food in normal and slow transit constipation. Dig Dis Sci 31 (abstr 1450): 365S
Arhan P, Devroede G, Jehamin B, Lanza M, Fareidin C, Dornic C, Phrsoz B, Tetreault L, Perey B, Pellerin D (1981) Segmental colonic transit time. Dis Colon Rectum 24: 625–629
Ehsanullah M, Lee DAH, Willimas T, Pollard P, Gazzard B (1985) The effect of secoverine hydrochloride on stimulated sigmoid motility: A double-blind, placebo controlled cross-over study in irritable bowel syndrome. Br J Clin Pharmacol 19: 301–305
NWA STATPAK multi-function statistics library, version 3.1. Northwest Analytical, Inc., Portland, Oregon 1984
Snape WI Jr, Wright SH, Battle WM, Cohen S (1979) The gastrocolic response: Evidence for a neural mechanism. Gastroenterology 77: 1253–1240
Lanfranchi GA, Bazzocchi G, Marzio L, Campieri M, Brignola C (1983) Inhibition of postprandial colonic motility by sulpiride in patients with irritable colon. J Clin Pharmacol 24: 769–772
Narducci F, Bassotti G, Gaburri M, Farconi F, Morelli A (1985) Nifedipine reduces the colonic motor response to eating in patients with the irritable bowel syndrome. Am J Gastroenterol 80: 317–319
Sun EA, Snape WJ Jr, Cohen S, Renny A (1982) The role of opiate receptors and cholinergic neurons. The gastrocolonic response. Gastroenterology 82: 689–693
Chowdhury AR, Lorben SH (1977) Effect of glucagon and secretin on food or morphine-induced motor activity of the distal colon, rectum and anal sphincter. Dig Dis 22: 775–780
Connel AM (1968) Alimentary canal. In: Code CF (ed) Handbook of physiology, IV. American Physiological Society, Washington DC, pp 2075–2091
Chaudary NA, Truelove SC (1961) Human colonic motility: A comparative study of normal subjects, patients with ulcerative colitis and patients with the irritable colon syndrome. I. Resting patterns of motility. Gastroenterology 40: 1–28
Litta Modigliani R, Mazzolari M, Berantani E, Bertoli D, Vibelli C (1978) Relative potency of the atropine-like effects of a new parasympatholytic drug, scopolamine N-(cyclopropylmethyl) bromide and those of hyoscine-N-butyl bromide. Curr Med Res Opin 5: 333–340
Bassotti G, Imbimbo BP, Gaburri M, Daniotti S, Morelli A (1987) Transverse and sigmoid colon motility in healthy humans: effects of eating and of cimetropium bromide. Digestion 37: 59–64
Narducci F, Bassotti G, Daniotti S, Del Soldato P, Pelli MA, Morelli A (1985) Identification of muscarinic receptor subtype mediating the colonic response to eating. Dig Dis Sci 30: 124–128
Imbimbo BP, Daniotti S, Vidi A, Foschi D, Saporiti F, Ferrante L (1986) Discontinuous oral absorption of cimetropium bromide, a new antispasmodic drug. J Pharm Sci 75: 680–684
Albano VMO, Gentonze V, Campanozzi F, Attolini E, Macinagrossa G, Imbimbo BP, Muzio F (1987) Oral cimetropium bromide (CB), a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. Gastroenterology 92: 1292
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lanfranchi, G.A., Bazzocchi, G., Campieri, M. et al. Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome. Eur J Clin Pharmacol 33, 571–575 (1988). https://doi.org/10.1007/BF00542489
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542489